JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…